AGP Picks
View all

New Mexico Health Reporter
Provided by AGP

New Mexico Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Health Reporter.

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

Press releases published on May 7, 2026

Alpha Pro Tech, Ltd. Announces First Quarter 2026 Financial Results
May 7, 2026

Alpha Pro Tech, Ltd. Announces First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Marius Pharmaceuticals Announces Key Leadership Expansion and Launch of Marius AI, Positioning the Company as the First AI-Native Pharmaceutical Company
May 7, 2026

Marius Pharmaceuticals Announces Key Leadership Expansion and Launch of Marius AI, Positioning the Company as the First AI-Native Pharmaceutical Company

Indeterminate GlobeNewswire
KALA BIO Announces Reverse Stock Split
May 7, 2026

KALA BIO Announces Reverse Stock Split

Indeterminate GlobeNewswire
Marlyn Expands Solid-Dose CDMO Capabilities with a Mechanistic-Integrity–Driven Manufacturing Platform
May 7, 2026

Marlyn Expands Solid-Dose CDMO Capabilities with a Mechanistic-Integrity–Driven Manufacturing Platform

Indeterminate GlobeNewswire
Biotech’s Next Wave May Already be in Motion
May 7, 2026

Biotech’s Next Wave May Already be in Motion

Indeterminate GlobeNewswire
Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026
May 7, 2026

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Indeterminate GlobeNewswire
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
May 7, 2026

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Indeterminate GlobeNewswire
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
May 7, 2026

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Indeterminate GlobeNewswire
Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
May 7, 2026

Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption

Indeterminate GlobeNewswire
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
May 7, 2026

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Indeterminate GlobeNewswire
Prenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
May 7, 2026

Prenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership

Indeterminate GlobeNewswire
SS Innovations Demonstrates Long-Distance Telesurgery Capabilities at Royal Australian College of Surgeons Annual Scientific Congress
May 7, 2026

SS Innovations Demonstrates Long-Distance Telesurgery Capabilities at Royal Australian College of Surgeons Annual Scientific Congress

Indeterminate GlobeNewswire
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
May 7, 2026

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market

Indeterminate GlobeNewswire
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 7, 2026

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

Indeterminate GlobeNewswire
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2026
May 7, 2026

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2026

Indeterminate GlobeNewswire
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
May 7, 2026

ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals

Indeterminate GlobeNewswire
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
May 7, 2026

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

Indeterminate GlobeNewswire
vTv Therapeutics to Participate in Upcoming May Investor Conferences
May 7, 2026

vTv Therapeutics to Participate in Upcoming May Investor Conferences

Indeterminate GlobeNewswire
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026

MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

Indeterminate GlobeNewswire
Stryker declares an $0.88 per share quarterly dividend
May 7, 2026

Stryker declares an $0.88 per share quarterly dividend

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

New Mexico Health Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.